GlaxoSmithKline Pharmaceuticals (GSK), a leading MNC in India, has achieved 6.9 per cent growth in net profit to Rs 141.08 crore during the third quarter ended September 2009 from Rs 131.97 crore in the corresponding period of last year. Its net sales improved by 12 per cent to Rs 511.81 crore from Rs 456.95 crore. Its EPS worked out to Rs 16.7 as against Rs 15.3 in the last period.

Commenting on the performance, Dr Hasit B Joshipura, managing director, said, “Sales during the quarter have shown growth across mass, mass speciality, vaccines and speciality therapies. Recent launches of Tykerb for refractory breast cancer, Benitec an anti-hypertensive drug from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth with the rotaviral diarrhoea vaccine tracking ahead of plan".

For the first nine months ended September 2009, GSK’s net sales increased by 10.4 per cent to Rs 1,426 crore from Rs 1,292 crore in the similar period of last year. The net profit went up by 11 per cent to Rs 408.70 crore from Rs 368.10 crore.